november AG

euro adhoc: november AG
Quarterly or Semiannual Financial Statements
november AG publishes positive consolidated net result for the first quarter 2005

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- 11.05.2005 First quarter 2005 with improved consolidated net result and group’s operating result Erlangen, 11 May 2005. For the quarter 2005, the Erlangen (Germany) based biotech company november AG (ISIN DE0006762909) reported a positive consolidated net result for the first time. The consolidated net result amounts to 0.08 million EUR which is equivalent to an improvement of 110 % compared to the previous year’s period (-0.8 million EUR). The group’s operating result (EBIT) before financial result, deferred taxes and minority interests of -0.3 million EUR also shows a significant improvement compared to the previous year’s figure (-1.27 Mio. EUR). Thus, the best quarterly net result since november AG’s IPO in April 2000 could be reached. In the first quarter 2005, november AG picked up where it left off last year in terms of positive business development. Quarterly group revenues rose to 1.4 million EUR thus exceeding the previous year’s figure by 19 % (1.1 million EUR). Due to successfully intensified marketing activities, sales and marketing expenses increased according to plan to 0.65 million EUR (0.57 million EUR). Simultaneously, research and development expenses could be reduced by 9 % to 0.67 million EUR (0.74 million EUR). At the end of the first three months, november AG’s total liquidity amounted to 7.5 million EUR. The balance sheet total at the end of the first quarter 2005 equalled 27.0 million EUR (27.7 million EUR). The net earnings per share (EPS and DVFA/SG) improved to EUR 0.01 (EUR -0.11). On average, 62 employees worked within the november Group throughout the reporting period from 1 January to 31 March 2005. This only includes employees working in companies that were fully consolidated. Annotation: november AG is an Erlangen (Germany) based listed biotech company (Frankfurt Stock Exchange Prime Standard, ISIN DE0006762909, SE symbol NBX) with, inter alia, a focus on development in the field of nanotechnology. Organized as a holding company, the group also includes the subsidiaries identif GmbH (product security & brand protection), directif GmbH (lab independent nucleic acid testing), and PEQLAB Biotechnologie GmbH (biotech R&D supplier). Since 2002, first brand protection products are available with pharma company Bristol-Myers Squibb (Germany) among the first customers. For diagnostics and based on a patented technology, directif GmbH develops the world's first fully integrated nucleic acid testing device which will provide fast and cost-efficient detection of pathogens on the genetic level even at the point of care. On a contractual basis, november will participate in the development of a novel immunotherapeutic approach to fight cancer through profit share options. This new therapy is being developed by responsif GmbH, the former therapeutic business unit of november AG whose management conducted a management buy-out in early 2003. end of announcement euro adhoc 11.05.2005 08:00:00 --------------------------------------------------------------------- Further inquiry note: Andrea Steuer Manager Investor Relations/Public Relations Tel.: +49(0)9131-75088-868 Fax: +49 (0)9131-75088-999 E-Mail: steuer@november.de Branche: Biotechnology ISIN: DE0006762909 WKN: 676290 Index: CDAX, Technologie All Share, Prime All Share, Prime Standard Börsen: Frankfurter Wertpapierbörse / regulated dealing Berliner Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade Bremer Wertpapierbörse (BWB) / free trade

Das könnte Sie auch interessieren: